Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2000 March;25(1) > Minerva Endocrinologica 2000 March;25(1):1-3





A Journal on Endocrine System Diseases

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118




Minerva Endocrinologica 2000 March;25(1):1-3

language: English

Plasmatic endo­the­lin-1 lev­els in hyper­thyr­oid ­patients ­before and ­after anti­thy­roid ther­a­py

Cesareo R. 1, Tarabuso A. 1, Di Benedetto M. 1, Lacerna F. 2, Reda G. 2

1 Division of Internal Medicine, Ciriè Hospital, Ciriè (Turin);
2 Division of Internal Medicine, S. Pertini Hospital, Rome


Background. The Endothelin-1 (ET-1) is a pow­er­ful vas­o­con­stric­tor pep­tide pro­duced by endo­the­lial ­cells in ­many vas­cu­lar dis­eas­es prob­ably as a ­response to ves­sel dam­age. In hyper­thyr­oi­dism as in oth­er endo­crin­o­log­i­cal dis­eas­es ele­vat­ed ET-1 plas­ma lev­els ­have ­been ­found.
Methods. The ­effect of anti­thy­roid ther­a­py on ET-1 plas­mat­ic lev­els was eval­u­at­ed by meas­ur­ing ET-1 plas­ma lev­els ­before and 2 and 6 ­months ­after treat­ment ­with methim­a­zole in 14 ­patients affect­ed by hyper­thyr­oi­dism.
Results. The hyper­thyr­oid ­patients had sig­nif­i­cant­ly high­er ET-1 lev­els ­than the con­trols (18.85±5.7 vs 10.9±2.1 pg/ml), ­while ­after treat­ment no dif­fer­ence was ­found. The ET-1 plas­ma lev­els of hyper­thyr­oid ­patients cor­re­lat­ed close­ly ­with the ­raised thy­roid meta­bol­ic activ­ity inde­pen­dent­ly of its ­cause. It is pos­sible ­that the ­increased ET-1 lev­els in hyper­thyr­oid ­patients are the expres­sion of ­blood ves­sel dam­age ­caused by ­high thy­roid hor­mone lev­els.
Conclusions. Moreover the ­results of ­this ­study ­could sug­gest ­that, in ­future, ET-1 plas­mat­ic lev­els ­might be con­sid­ered as a func­tion­al thy­roid ­index in hyper­thyr­oid dis­eas­es.

top of page

Publication History

Cite this article as

Corresponding author e-mail